<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252170</url>
  </required_header>
  <id_info>
    <org_study_id>BCI-10-001</org_study_id>
    <secondary_id>5R44AG044639-05</secondary_id>
    <nct_id>NCT04252170</nct_id>
  </id_info>
  <brief_title>Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly</brief_title>
  <official_title>Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly (Feasibility Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bright Cloud International Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genesis HealthCare System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bright Cloud International Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research project is intended to provide information pertaining to the feasibility of the&#xD;
      BrightArm Compact robotic rehabilitation system for patients early sub-acute post Cerebral&#xD;
      Vascular Accident. The aims are to: a) determine clinical benefit to motor and cognitive&#xD;
      function as well as mood; 2) to ascertain technology acceptance by patients and therapists.&#xD;
      The experimental training consists of 12 integrative arm/hand and cognitive training by&#xD;
      playing therapeutic games. Participants are evaluated pre-and post-intervention and provide&#xD;
      subjective evaluation of the system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study targets participants, who had suffered a first stroke recently, and who may or may&#xD;
      not have been diagnosed with mild cognitive impairments or dementia (including Alzheimer's&#xD;
      disease). It is important to find out if these improvements can be obtained with the computer&#xD;
      game-based integrative (motor-cognitive) bilateral rehabilitation developed by Bright Cloud&#xD;
      International Corp, and if these gains transfer to daily activities.&#xD;
&#xD;
      Specific aims are:&#xD;
&#xD;
        -  BAC technology acceptance;&#xD;
&#xD;
        -  improvement in motor function for the upper extremity;&#xD;
&#xD;
        -  strengthening of shoulder and fingers;&#xD;
&#xD;
        -  increased active (self initiated) range of motion for shoulder, arms and fingers;&#xD;
&#xD;
        -  improved independence in activities of daily living;&#xD;
&#xD;
        -  improvement in cognitive areas of memory, attention and decision making;&#xD;
&#xD;
        -  improved mood (as in reduced depression severity);&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2018</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>6 will be stroke survivors inpatients at PowerBack, Piscataway NJ, USA.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Artificial Intelligence-determined game difficulty level</measure>
    <time_frame>Through study completion, an average of 3 weeks</time_frame>
    <description>BrightBrainer game difficulty setting is determined based on patient's past performance, in order to adapt the therapy to a given individual. It representing an average or difficulties of all games played in a session. The measure implies game play intensity and level of challenge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Game Score (baseline and performance)</measure>
    <time_frame>Through study completion, an average of 3 weeks</time_frame>
    <description>BrightBrainer game baseline and performance scores. Min. score is 0. Max depends on specific game.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants' feedback using 5-point Likert scale</measure>
    <time_frame>Through study completion, an average of 3 weeks</time_frame>
    <description>Subjective evaluation feedback and overall ratings on BrightBrainer games. Consists of multiple questions, each ranked on a 5-point Likert scale, with 1 (min) and 5 (max).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapist subjective evaluation using 5-point Likert scale</measure>
    <time_frame>3 weeks</time_frame>
    <description>Subjective evaluation given by the attending Occupational Therapist at the end of the experimental intervention. Multiple questions, each ranked from 1 (min) to 5 (max)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arm Range of Motion</measure>
    <time_frame>Change from Baseline arm range of motion at 3 weeks</time_frame>
    <description>measurement of active movement initiated by participant using a mechanical goniometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Finger Range of Motion</measure>
    <time_frame>Change from Baseline finger range of motion at 3 weeks</time_frame>
    <description>finger extension/flexion range using a mechanical goniomter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grasp Strength with Jamar Dynamo-meter</measure>
    <time_frame>Change from Baseline grasp strength at 3 weeks</time_frame>
    <description>grasp strength measurement using dynamo-meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pinch strength with pinch meter</measure>
    <time_frame>Change from Baseline at 3 weeks</time_frame>
    <description>Pinch strength measured with fingers placed on a pinch meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder strength</measure>
    <time_frame>Change from Baseline shoulder strength at 3 weeks</time_frame>
    <description>Measurement of shoulder strength using calibrated wrist weights</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment (Upper Extremity sub-scale) score</measure>
    <time_frame>Change from Baseline Fugl-Meyer Assessment Score at 3 weeks</time_frame>
    <description>Upper Extremity Motor function, score scale is 0 (min) to 66 (max). Larger score means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper extremity functional index (UEFI) score</measure>
    <time_frame>Change from Baseline Upper Extremity Functional Inex score at 3 weeks</time_frame>
    <description>A self report of independence in 20 activities of daily living (ADLs). Total score range is 0 (min) to 80 (max). Larger score means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAHAI 9 Score</measure>
    <time_frame>Change from Baseline CAHAI 9 score at 3 weeks</time_frame>
    <description>Chedoke Arm and Hand Activity Inventory, reflecting ADL independence in simulated bimanual activities. Min score 9, max score 63, with larger score meaning better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Jebsen Test of Hand Function</measure>
    <time_frame>Change from Baseline Jebsen Test of Hand Function score at 3 weeks</time_frame>
    <description>Timed test of 7 simulated activities of daily living. Lowest score is 0, largest score is 1260. Units are seconds. Lower score means better outcomes (faster completion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II (BDI II) score</measure>
    <time_frame>Change from Baseline depression severity at 3 weeks</time_frame>
    <description>participants' depression measure. Range is 0 (min) to 63 (max). Lower score indicate better outcomes (less depression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal attention</measure>
    <time_frame>Change from Baseline verbal attention at 3 weeks</time_frame>
    <description>Attention module digit span (working memory) in the Neuropsychological Assessment Battery NAB min 0, larger score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal fluency</measure>
    <time_frame>Change from Baseline verbal fluency at 3 weeks</time_frame>
    <description>verbal fluency test min 0, larger score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal memory</measure>
    <time_frame>Change from Baseline verbal learning memory at 3 weeks</time_frame>
    <description>Hopkins Verbal Learning Test, Revised (HVLT-R) min 0, larger is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Visuospatial Memory Test-Revised</measure>
    <time_frame>Change from Baseline visuospatial memory at 3 weeks</time_frame>
    <description>A measure of memory function min 50 std of 10, larger score is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive Function Module</measure>
    <time_frame>Change from Baseline executive function at 3 weeks</time_frame>
    <description>Word Generation min 0, larger is better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive executive function</measure>
    <time_frame>Change from Baseline Trail Making Test B (TMT-B) Score at 3 weeks</time_frame>
    <description>Trail Making Test B (TMT-B) lMin 50, std of 10, larger number means better outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive executive function</measure>
    <time_frame>Change from Baseline NAB Exec Score at 3 weeks</time_frame>
    <description>NAB Executive Functioning Module min 50, std is 10, larger number means better outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual attention</measure>
    <time_frame>Change from Baseline visual attention at 3 weeks</time_frame>
    <description>Attention module dots (visual) in the Neuropsychological Assessment Battery NAB</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Feasibility study, Stroke Survivors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAC feasibility study at PowerBack, Piscataway NJ, with stroke patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rehabilitation Therapy, Experimental on the BrightArm Compact device</intervention_name>
    <description>Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.</description>
    <arm_group_label>Feasibility study, Stroke Survivors</arm_group_label>
    <other_name>BrightArm Compact rehabilitation through games</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 50 to 85;&#xD;
&#xD;
          -  diagnosis of first-time CVA that occurred more than 5 days prior and less than 21 days&#xD;
             prior&#xD;
&#xD;
          -  English speakers;&#xD;
&#xD;
          -  UE unilateral or bilateral involvement (from new bilateral CVA)&#xD;
&#xD;
          -  motor involvement (FMA score 20 to 45);&#xD;
&#xD;
          -  ability to actively move UE more than 10 degrees for shoulder and elbow&#xD;
             flexion/extension;&#xD;
&#xD;
          -  ability to actively extend fingers at least 5 degrees&#xD;
&#xD;
          -  cognitive skills to participate (Montreal Cognitive Assessment (MoCA) [Nasreddine et&#xD;
             al 2005] score 10-30).&#xD;
&#xD;
          -  Subjects may have normal cognition, MCI or dementia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  being younger than 50 or older than 85 years of age&#xD;
&#xD;
          -  previous stroke&#xD;
&#xD;
          -  Stroke that occurred more than 20 days prior to enrollment&#xD;
&#xD;
          -  Inability to actively extend fingers at least 5 degrees;&#xD;
&#xD;
          -  Fugl-Meyer scores of 19 or less;&#xD;
&#xD;
          -  severe visual neglect or legally blind&#xD;
&#xD;
          -  severe hearing loss or deafness&#xD;
&#xD;
          -  receptive aphasia or severe expressive aphasia;&#xD;
&#xD;
          -  severe spasticity (Modified Ashworth Scale 4/4)&#xD;
&#xD;
          -  contractures of the upper limb joints&#xD;
&#xD;
          -  uncontrolled hypertension (&gt;190/100 mmHg)&#xD;
&#xD;
          -  severe cognitive impairment determined by Montreal Cognitive Assessment (MoCA)&#xD;
             [Nasreddine et al, 2005] test of 9 and below;&#xD;
&#xD;
          -  No chemodenervation or nerve block to upper limb involved during the experimental&#xD;
             period (e.g., botulinum toxin injection)&#xD;
&#xD;
          -  inability to speak English;&#xD;
&#xD;
          -  a history of violence or drug abuse;&#xD;
&#xD;
          -  paranoia and psychotic behavior;&#xD;
&#xD;
          -  inability participate in the neuropsychological pre-study assessment for reliable&#xD;
             scores (e.g., cognitive impairment, communication disorders).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grigore C Burdea, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>BRIGHT CLOUD INTL CORP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PowerBack Rehabilitation</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.BrightBrainer.com</url>
    <description>BCI's corporate site</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bright Cloud International Corp</investigator_affiliation>
    <investigator_full_name>Dr. Nam H. Kim</investigator_full_name>
    <investigator_title>Director of Engineering</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT04252170/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT04252170/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

